Stefan Hendricks

Senior Vice President Global Head Cell & Gene Therapy • Novartis

Stefan Hendriks is Global Head Cell & Gene and a member of the Oncology Leadership Team. In this role, Stefan is responsible for leading a cross-functional and cross-divisional team in Cell & Gene Therapies, reporting to Susanne Schaffert, President of Novartis Oncology. His responsibilities cover clinical development, manufacturing, medical affairs, commercial activities and the development & execution of Novartis strategy in Cell & Gene Therapies in oncology. Prior to this, Stefan was Global Head of Biopharmaceuticals at Sandoz. In this role, Stefan was responsible for the development and commercialization of biopharmaceuticals, including biosimilars. Sandoz has eight biosimilars approved in total, and under Stefan’s guidance, the team launched three biosimilars in 2018 and continued to invest and expand the leading portfolio including into underserved therapy areas such as insulins. Stefan brings considerable experience in launch excellence and team leadership as well as brand and franchise management with over 20 years of serving in the pharmaceutical industry. He believes in unlocking the potential of each individual by focusing on a growth mindset, and creating an environment that is collaborative, curious and patient-and customer-centric. Prior to joining Novartis Stefan worked at Bristol-Myers Squibb (BMS) where he held numerous country, regional and global roles across sales, marketing and general management for 15 years, and previously also worked for AstraZeneca. He has deep therapeutic area experience spanning immunology, oncology, endocrinology, virology, cardiovascular, and respiratory among others. Stefan received a business administration degree from the Royal Military Academy of the Netherlands in 1992. He also completed two postgraduate programs in Sales and Account Management from Erasmus University in Rotterdam, Netherlands and in Strategy in the Pharmaceutical Industry from theUniversity Wageningen, Netherlands. Stefan also holds a degree in General Management Program, cedep INSEAD, Fontainebleau.

Also speaking

John Campbell

Director, Tissues Cells & Advanced Therapeutics • Scottish National Blood Transfusion Service

Michael Delahaye

Director, Team Leader, Cell Therapy Bioprocessing • AstraZeneca

Michael von Forstner

Global Head of Clinical Safety and Pharmacovigilance • Biogen

Event Info


Spotlight Roundtables

Take a look at the sample attendee list for Advanced Therapies Europe here.

Pub & Pints RSVP

Let us know you’re planning on attending.